Incannex Healthcare Limited (ASX:IHL)
Incannex Healthcare Limited (ASX:IHL) is a clinical stage pharmaceutical company developing medicinal cannabis products and psychedelic medicine therapies for the treatment of Generalised Anxiety Disorder (GAD), Obstructive Sleep Apnoea (OSA), Traumatic Brain Injury (TBI)/Concussion and Acute Respiratory Distress Syndrome (ARDS).
FDA registration is being pursued for each product and therapy under development. Each indication represents major global markets and currently have no, or limited, existing registered pharmacotherapy (drug) treatments available.
Incannex has a strong patent filing strategy (as announced in October 2019, IHL files cannabinoid patent over IHL-216A for TBI and in December 2019, IHL Files Patent over IHL-42X for OSA). Further to its clinical programs, Incannex has its Australian license to import, export and distribute medicinal cannabis products and has launched a line of cannabinoid oil products. The cannabis-based oils are sold under Incannex’s distribution agreement with Cannvalate Pty Ltd, owner of the largest network of cannabis medicine prescribers in Australia and a major shareholder of Incannex.